Hepatitis Testing Market Size to Reach USD 5.75 Billion by 2032 Driven by Rising Prevalence, Early Detection Demand, and Technological Advancements
Austin, July 18, 2025 (GLOBE NEWSWIRE) -- Hepatitis Testing Market Size & Growth Analysis:
According to SNS Insider, the global Hepatitis Testing Market was valued at USD 3.53 billion in 2023 and is projected to reach USD 5.75 billion by 2032, growing at a CAGR of 5.62% during the forecast period 2024-2032.
The global hepatitis testing market is growing significantly due to the increasing incidence of hepatitis B and C infections, growing awareness around early diagnosis, and government-driven screening programs. Further, technological improvements in serological and molecular testing have enhanced test sensitivity and turnaround times, contributing to market growth.Request Your Free Sample Copy of the Hepatitis Testing Market Report Today: https://www.snsinsider.com/sample-request/4692
The U.S. accounted for a substantial portion of the global market, valued at USD 1.22 billion in 2023, and is projected to reach USD 1.94 billion by 2032. This dominance is attributed to the presence of major diagnostic players, high healthcare spending, and a robust testing infrastructure across hospitals and diagnostic laboratories.
Market Overview
The hepatitis testing market is growing owing to the increase in demand for accurate diagnostic products, especially with the increase in the number of global hepatitis infections. Public health organizations such as the WHO and CDC are promoting mass screening and early diagnosis policies, extending the scope and frequency of hepatitis testing across the globe. Multitarget detection has changed the testing landscape with respect to hepatitis viruses in recent years, especially due to advancements in immunoassay and PCR-based diagnostics that now allow simultaneous testing.
Furthermore, growing trend towards integrated healthcare systems and government initiatives for reimbursement policies will encourage the adoption of diagnosis testing kits. Developed regions such as North America and Europe with well-established laboratory networks and insurance policies conducive to mass screening. At the same time, low and middle-income countries are fast catching up because of increased awareness and international healthcare partnerships. The rising interest in point-of-care testing and home-use testing products will also drive long-term market growth in the next ten years.
Major Players Analysis Listed in this Report are:
Abbott Laboratories (Architect Anti-HCV, Alinity HCV)
Analytik Jena (AdiSelect HCV, AdiSelect HCV Real-Time PCR Kit)
Autobio Diagnostics (HCV Antibody Test Kit, HEV Antibody Test Kit
Bio-Mérieux (VIDAS Anti-HCV, VIDAS HEV)
Danaher Corporation (Cepheid Xpert HCV, LumiraDx HCV Test)
DiaSorin (LIAISON HCV, LIAISON HCV)
Grifols SA (Procleix HCV Assay, Procleix HEV Assay)
Hologic Inc. (Aptima HCV Assay, Aptima HEV Assay)
MedMira Inc. (Reveal HCV Test, Reveal HEV Test)
Ortho-Clinical Diagnostics (Vitros Anti-HCV Test, Vitros HEV Test)
Qualpro Diagnostics (HCV Rapid Test, HEV Rapid Test)
Roche Molecular Diagnostics (Cobas HCV Test, Cobas HEV Test
Siemens Healthcare (ADVIA Centaur HCV, Dimension Vista HEV)
Sysmex Corporation (Sysmex HCV Test, Sysmex HCV Test)
Thermo Fisher Scientific (TaqMan HCV Test, HCV Viral Load Test)
PerkinElmer (HCV Viral Load Test, HEV Serology Test)
Qiagen (QIAstat-Dx Respiratory Panel, QIAamp Viral RNA Mini Kit)
Becton, Dickinson and Company (BD) (BD MAX HCV Test, BD Veritor System forHCV)
Myriad Genetics (Myriad RBM HCV Antibody Test, F. Hoffmann-La Roche LtD
Hepatitis Testing Market Report Scope
Report Attributes
Details
Market Size in 2023
US$ 3.53 billion
Market Size by 2032
US$ 5.75 billion
CAGR (2024–2032)
5.62%
U.S. Market 2023
USD 1.22 billion
U.S. Forecast by 2032
USD 1.94 billion
Base Year
2023
Forecast Period
2024–2032
Key Regional Coverage
North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Segment Analysis
By Test:
In 2023, the highest proportion of the diagnostic methods preferred for hepatitis detection was blood tests, which is primarily due to their non-invasive nature, high accuracy, and suitability for the detection of various hepatitis virus types (HBV, HCV, HAV, HEV). These tests are commonly used in hospitals and labs to screen for disease on a large scale.
Imaging Studies Imaging procedures (primarily not used for diagnostic purposes) include ultrasound sonography and elastography, which are developing at a remarkable pace, especially in the context of the management of chronic viral hepatitis in the assessment of liver fibrosis.
By Technology:
ELISA technology dominated due to its dependable nature, cost-effectiveness, and production of high-throughput tests. It is a widely used method for the detection of hepatitis antigens and antibodies in all healthcare facilities.
The PCR is more and more widely used as it is unequaled in sensitivity and accuracy, competing with viral RNA/DNA potentially at its early stage for a precise diagnosis and follow-up of patients.
By End User:
The Hospitals and Diagnostic Laboratories market is the largest revenue-generating testing location on account of a wider reach (hence greater accessibility), presence of high-end laboratory equipment for testing, and alignment with insurance-based payment models.
The Home care segment is augmenting in the domestic hepatitis devices market as the preference for self-testing, home diagnostic kits, and remote care health monitoring grows among chronic hepatitis patients and the at-risk population.
By Product:
Reagents and Kits (60% contribution in 2023): Reagents and kits will continue to be at the centre-stage of hepatitis testing protocols, given their high utilization, the need for re-testing, and product advancements that increase test accuracy and reliability.
Instruments: Increasing technology for automating tests, particularly in PCR and immunoassay systems, is a key growth driver for instruments in centralized and decentralized diagnostic locations.
For a Personalized Briefing with Our Industry Analysts, Connect Now: https://www.snsinsider.com/request-analyst/4692
Hepatitis Testing Market Segmentation
By Test
Blood tests
Imaging tests
Liver Biopsy
By Technology
Enzyme-linked immunosorbent assay (ELISA)
Rapid Diagnostic Test
Polymerase Chain Reaction (PCR)
Isothermal Nucleic Acid Amplification Technology (INAAT)
Others
By End Use
Hospitals & Diagnostic Labs
Blood Banks
Others
By Product
Instruments
Reagents & Kits
Regional Analysis
In 2023, North America accounted for the largest share of the hepatitis testing market, with 43% of the global share, mainly due to high awareness levels, organized screening programs, and investments in the development of advanced diagnostic technologies.
The APAC market is projected to witness the highest growth rate during the forecast period, due to the rising prevalence of hepatitis B and C, developed healthcare infrastructure, and favorable government policies in countries such as China, India, and Southeast Asia.
Recent Developments
In November 2023, F. Hoffmann-La Roche Ltd Two automated serology tests for hepatitis E diagnosis (Elecsys Anti-HEV IgM, IgG). These tests are among those on WHO's Essential Diagnostics List.
In April 2024, BioMérieux unveiled a fully automated hepatitis B and C multiplex assay on its VIDAS platform, which is expected to offer a faster turnaround time in clinical labs.
In March 2024, Abbott Laboratories designed an enhanced version of its RealTime HCV test on the m2000 platform to further increase sensitivity for low viral load ranges.Buy the Full Hepatitis Testing Market Report (Single-User License) Now: https://www.snsinsider.com/checkout/4692
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. Hepatitis Testing Market by Type
8. Hepatitis Testing Market by Technology
9. Hepatitis Testing Market by End Use
10. Hepatitis Testing Market by Product
11. Regional Analysis
12. Company Profiles
13. Use Cases and Best Practices
14. Conclusion
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Patterson-UTI (PTEN): Among the Best Oil and Gas Stocks for Dividend Income
Patterson-UTI Energy, Inc. (NASDAQ:PTEN) is included among the 12 Best Oil and Gas Dividend Stocks to Buy Now. A drilling site in the wilds of nature, highlighting the company's commitment to exploration. Following its 2023 acquisition of Nextier, Patterson-UTI Energy, Inc. (NASDAQ:PTEN) has emerged as a dominant player in US drilling and completions, boasting the country's largest pressure pumping fleet. The company returned $51 million to shareholders in the first quarter of 2025, including $20 million for share repurchases. PTEN also declared a quarterly dividend of $0.08 per share in April and offers an attractive annual dividend yield of 5.37% as of the writing of this piece. Over the 18 months from September 30, 2023, through March 31, 2025, Patterson-UTI Energy, Inc. (NASDAQ:PTEN) used approximately $387 million to repurchase shares and reduced its share count by 8%. The company still has $741 million in remaining share repurchase authorization as of the end of the first quarter of 2025. PTEN revealed in its investor presentation last month that it has a target to return at least 50% of this adjusted free cash flow to shareholders, supported by a strong capital structure with no senior note maturities until 2028. Patterson-UTI Energy, Inc. (NASDAQ:PTEN) is a leading provider of drilling and completion services to oil and natural gas exploration and production companies in the United States and other select countries. While we acknowledge the potential of PTEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Nuclear Energy Stocks to Buy Right Now and The 5 Energy Stocks Billionaires are Quietly Piling Into. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Shares of Brazil's Fleury jump on reports of talks with Rede D'Or
SAO PAULO (Reuters) -Shares of Brazilian medical diagnostics company Fleury jumped on Monday after reports of a potential acquisition by hospital chain Rede D'Or, which analysts said could generate synergies. Fleury's shares rose more than 15% in trading in Sao Paulo, making it the biggest gainer on benchmark stock index Bovespa, which was up 0.6%. Rede D'Or, meanwhile, gained 1.2%. Multiple local media outlets said on Sunday that Rede D'Or was in talks with Fleury on a deal that could combine Brazil's largest integrated healthcare network with a leading medical lab chain. Brazil Journal reported, citing sources, that Rede D'Or was working on an offer that could include both a cash payment and share swap. Fleury counts lender Bradesco as one of its main shareholders. Rede D'Or said on Monday it continuously evaluates opportunities to expand, including potential acquisitions or business combinations, but that no decision or proposal had been made for a potential deal with Fleury. In a separate statement, Fleury said it regularly analyzes market conditions but also noted that no decision had been reached on a potential transaction with Rede D'Or. Goldman Sachs analysts said Fleury could benefit under Rede D'Or's management from better procurement terms, especially on materials, in which there would be some overlap, and a leaner general and administrative structure. Fleury has a market capitalization of 6.91 billion reais ($1.24 billion), while Rede D'Or's market cap stands at 75.29 billion reais, according to LSEG data. Rede D'Or in 2022 acquired insurer SulAmerica in a deal worth 13 billion reais, part of a trend for consolidation in Brazil's healthcare sector that saw the hospital chain as one of the most active companies in recent years. Analysts at Santander said a deal between Fleury and Rede D'Or would make sense from a strategic point of view. "Main synergies could be related to higher scale, and therefore more bargaining power to buy materials at Fleury and G&A savings," they said. ($1 = 5.5704 reais) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
The Best $250 You Can Spend on Retirement Planning Before the End of 2025
Do you feel like you're grappling in the dark when it comes to retirement planning but aren't sure where to turn or if you should spend money to get those plans in order? If you have even a few hundred dollars, there are a few ways you can use that money to make a significant difference in your retirement goals. Be Aware: Read Next: Christopher Stroup, a CFP and owner of Silicon Beach Financial, offered tips on the best $250 or less you can spend on your retirement planning before this year is up to feel confident in where you're going. An Hour With a Fiduciary Advisor If you only have a couple hundred dollars to spend, Stroup recommended you spend it on a one-time planning session with a fiduciary advisor who specializes in retirement planning. 'A targeted session can identify overlooked tax strategies, prioritize savings vehicles and help avoid costly missteps,' he explained. Even just a single hour of personalized advice can provide more clarity than weeks of online research, especially for entrepreneurs or tech professionals navigating equity, cash flow and multiple income sources, he said. 'Look for advisors who offer project-based or hourly services and focus on tax strategy, Social Security and withdrawal planning,' he said. You should come away from a one-time session 'with clarity, not a sales pitch.' Learn More: A Social Security Timing Analysis Another great way to spend a few hundred dollars is to get a Social Security timing analysis, Stroup said. 'For under $250, you can model break-even ages, spousal benefits and the impact of delaying benefits.' This analysis is important because this single decision can mean tens of thousands more over your lifetime, especially for dual-income households or individuals with uneven earnings histories, Stroup explained. Strategic Tax Planning If you feel you have more questions for a fiduciary advisor than can be summed up in an hour, consider focusing the session around strategic tax planning, Stroup urged. This can help you avoid future Medicare surcharges, minimize required minimum withdrawal (RMD) taxes and better time Roth conversions. 'A well-timed projection can reveal opportunities that disappear at retirement or when tax brackets shift. Spending a few hundred now can prevent five-figure tax mistakes later.' Invest In Planning Tools, but Be Cautious For a low annual cost, tools like Boldin's retirement planning tool allow users to stress-test income scenarios, Social Security timing, Roth conversions and healthcare costs, Stroup said. Retirement planning tools that map out your income, expenses and drawdown strategy can be useful. They can also help you understand your 'burn rate' and how to sequence withdrawals to prevent common missteps that derail early retirement plans. However, Stroup warned that the simpler, more DIY tools can make it too easy to 'underestimate taxes on withdrawals, mistime Social Security or hold too much in cash or high-fee funds.' Thus, a small investment in expert guidance or advanced planning software can flag these risks early before they compound over decades. More From GOBankingRates How Much Money Is Needed To Be Considered Middle Class in Your State? This article originally appeared on The Best $250 You Can Spend on Retirement Planning Before the End of 2025 Sign in to access your portfolio
